374 results on '"Bossios Apostolos"'
Search Results
2. Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC)
- Author
-
Polverino, Eva, Dimakou, Katerina, Traversi, Letizia, Bossios, Apostolos, Haworth, Charles S., Loebinger, Michael R., De Soyza, Anthony, Vendrell, Montserrat, Burgel, Pierre-Régis, Mertsch, Pontus, McDonnell, Melissa, Škrgat, Sabina, Maiz Carro, Luis, Sibila, Oriol, van der Eerden, Menno, Kauppi, Paula, Hill, Adam T., Wilson, Robert, Milenkovic, Branislava, Menendez, Rosario, Murris, Marlene, Digalaki, Tonia, Crichton, Megan L., Borecki, Sermin, Obradovic, Dusanka, Nowinski, Adam, Amorim, Adelina, Torres, Antoni, Lorent, Natalie, Welte, Tobias, Blasi, Francesco, Van Braeckel, Eva, Altenburg, Josje, Shoemark, Amelia, Shteinberg, Michal, Boersma, Wim, Elborn, J. Stuart, Aliberti, Stefano, Ringshausen, Felix C., Chalmers, James D., and Goeminne, Pieter C.
- Published
- 2024
- Full Text
- View/download PDF
3. Effect of simulated gastro-duodenal digestion on the allergenic reactivity of beta-lactoglobulin
- Author
-
Bossios Apostolos, Theodoropoulou Maria, Mondoulet Lucie, Rigby Neil M, Papadopoulos Nikolaos G, Bernard Hervé, Adel-Patient Karine, Wal Jean-Michel, Mills Clare EN, and Papageorgiou Photini
- Subjects
in vitro digestion ,cow's milk allergy ,β-lactoglobulin ,flow cytometry ,Basophil activation ,skin prick test ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background Cow's milk (CM) allergy affects about 2% of infants. The allergenicity of dietary proteins, including those from CM, has been related to their digestibility although the generality of the link and its causality remains to be demonstrated. In this study we use an in vitro digestion system, to investigate the digestibility of β-lactoglobulin (blg) during gastrointestinal transit and to assess the impact of this process on blg allergenic reactivity in CM allergic children. Methods Blg digesta were prepared using an in vitro digestion protocol simulating either gastric digestion alone or followed by duodenal digestion with or without phosphatidylcholine (PC). Biochemical analysis of blg digesta was performed by SDS-PAGE and their concentration was measured by a sandwich ELISA. Assessment of their allergenic reactivity was done in vitro by EAST inhibition, specific basophil activation (basotest) and lymphocyte proliferation (PCNA-flow cytometry) assays using sera and cells from patients allergic to blg and in vivo by skin prick testing (SPT) of these patients. Results Blg was only broken down to smaller peptides after gastro-duodenal digestion although a sizeable amount of intact protein still remained. Digestion did not modify the IgE binding capacity of blg except for gastro-duodenal digestion performed in the absence of PC. These results are consistent with the quantity of intact blg remaining in the digesta. Overall both gastric and gastroduodenal digestion enhanced activation of sensitized basophils and proliferation of sensitized lymphocytes by blg. However, there was a tendency towards reduction in mean diameter of SPT following digestion, the PC alone during phase 1 digestion causing a significant increase in mean diameter. Conclusions Digestion did not reduce the allergenic reactivity of blg to a clinically insignificant extent, PC inhibiting digestion and thereby protecting blg allergenic reactivity. SPT reactivity was reduced compared to blg immunoreactivity in in vitro tests.
- Published
- 2011
- Full Text
- View/download PDF
4. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages
- Author
-
Gabrielsson Susanne, Sjöstrand Margareta, Bossios Apostolos, Torregrosa Paredes Patricia, Eldh Maria, Ekström Karin, Seyed Alikhani Vesta, Lässer Cecilia, Lötvall Jan, and Valadi Hadi
- Subjects
Medicine - Abstract
Abstract Background Exosomes are 30-100 nm membrane vesicles of endocytic origin produced by numerous cells. They can mediate diverse biological functions, including antigen presentation. Exosomes have recently been shown to contain functional RNA, which can be delivered to other cells. Exosomes may thus mediate biological functions either by surface-to-surface interactions with cells, or by the delivery of functional RNA to cells. Our aim was therefore to determine the presence of RNA in exosomes from human saliva, plasma and breast milk and whether these exosomes can be taken up by macrophages. Method Exosomes were purified from human saliva, plasma and breast milk using ultracentrifugation and filtration steps. Exosomes were detected by electron microscopy and examined by flow cytometry. Flow cytometry was performed by capturing the exosomes on anti-MHC class II coated beads, and further stain with anti-CD9, anti-CD63 or anti-CD81. Breast milk exosomes were further analysed for the presence of Hsc70, CD81 and calnexin by Western blot. Total RNA was detected with a Bioanalyzer and mRNA was identified by the synthesis of cDNA using an oligo (dT) primer and analysed with a Bioanalyzer. The uptake of PKH67-labelled saliva and breast milk exosomes by macrophages was examined by measuring fluorescence using flow cytometry and fluorescence microscopy. Results RNA was detected in exosomes from all three body fluids. A portion of the detected RNA in plasma exosomes was characterised as mRNA. Our result extends the characterisation of exosomes in healthy humans and confirms the presence of RNA in human saliva and plasma exosomes and reports for the first time the presence of RNA in breast milk exosomes. Our results also show that the saliva and breast milk exosomes can be taken up by human macrophages. Conclusions Exosomes in saliva, plasma and breast milk all contain RNA, confirming previous findings that exosomes from several sources contain RNA. Furthermore, exosomes are readily taken up by macrophages, supporting the notion that exosomal RNA can be shuttled between cells.
- Published
- 2011
- Full Text
- View/download PDF
5. Quantitative expression of osteopontin in nasal mucosa of patients with allergic rhinitis: effects of pollen exposure and nasal glucocorticoid treatment
- Author
-
O'Neil Serena E, Malmhäll Carina, Samitas Konstantinos, Pullerits Teet, Bossios Apostolos, and Lötvall Jan
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background Osteopontin (OPN) is a multifunctional cytokine that has been primarily investigated in Th1 diseases. Recently, it has also been implicated in Th2-mediated allergic diseases, such as asthma. The expression of OPN in allergic rhinitis (AR) is currently unknown, as is the effect of intranasal glucocorticosteroids (GCs) on that expression. Methods Subjects with AR were randomised to receive treatment with fluticasone propionate (FP) (n = 12) or a placebo (n = 16) over the grass pollen season and nasal biopsies were taken prior to, and during the season. OPN expression in the nasal mucosa was examined with immunohistochemistry. Healthy non-AR controls (n = 5) were used as a comparator. Results OPN expression was detected in epithelial cells, subepithelial infiltrating/inflammatory cells and cells lining the vessels and glands of all subjects. Comparison of the pre- and peak-pollen season biopsy sections in placebo treated patients revealed no increase in OPN expression during the grass pollen season (5.7% vs 6.4%). Treatment with a local glucocorticosteroid did not alter the expression of OPN during pollen exposure (6.2% vs 6.7%). Conclusion OPN has been increasingly associated with the pathogenesis of various Th2-mediated diseases. However, our finding that the OPN expression in the nasal mucosa of AR patients is not significantly affected by allergen exposure and is comparable to that of the healthy controls, suggests that intracellular OPN is not directly involved in the pathogenesis of allergic rhinitis.
- Published
- 2010
- Full Text
- View/download PDF
6. Regulatory role of CD8+ T lymphocytes in bone marrow eosinophilopoiesis
- Author
-
Bossios Apostolos, Malmhäll Carina, Johansson Anna-Karin, Sergejeva Svetlana, Rådinger Madeleine, Sjöstrand Margareta, Lee James J, and Lötvall Jan
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background There is a growing body of evidence to suggest that CD8+ T lymphocytes contribute to local allergen-induced eosinophilic inflammation. Since bone marrow (BM) responses are intricately involved in the induction of airway eosinophilia, we hypothesized that CD8+ T lymphocytes, as well as CD4+ T lymphocytes, may be involved in this process. Methods Several approaches were utilized. Firstly, mice overexpressing interleukin-5 (IL-5) in CD3+ T lymphocytes (NJ.1638; CD3IL-5+ mice) were bred with gene knockout mice lacking either CD4+ T lymphocytes (CD4-/-) or CD8+ T lymphocytes (CD8-/-) to produce CD3IL-5+ knockout mice deficient in CD4+ T lymphocytes (CD3IL-5+/CD4-/-) and CD8+ T lymphocytes (CD3IL-5+/CD8-/-), respectively. Secondly, CD3+, CD4+ and CD8+ T lymphocytes from naïve CD3IL-5+ and C57BL/6 mice were adoptively transferred to immunodeficient SCID-bg mice to determine their effect on BM eosinophilia. Thirdly, CD3IL-5+, CD3IL-5+/CD8-/- and CD3IL-5+/CD4-/- mice were sensitized and allergen challenged. Bone marrow and blood samples were collected in all experiments. Results The number of BM eosinophils was significantly reduced in CD3IL-5+/CD8-/- mice compared to CD3IL-5+ mice and CD3IL-5+/CD4-/- mice. Serum IL-5 was significantly higher in CD3IL-5+/CD4-/- mice compared to CD3IL-5+ mice but there was no difference in serum IL-5 between CD3IL-5+/CD4-/- and CD3IL-5+/CD8-/- mice. Adoptive transfer of CD8+, but not CD4+ T lymphocytes from naïve CD3IL-5+ and C57BL/6 mice restored BM eosinophilia in immunodeficient SCID-bg mice. Additionally, allergen challenged CD3IL-5+/CD8-/- mice developed lower numbers of BM eosinophils compared to CD3IL-5+ mice and CD3IL-5+/CD4-/- mice. Conclusion This study shows that CD8+ T lymphocytes are intricately involved in the regulation of BM eosinophilopoiesis, both in non-sensitized as well as sensitized and allergen challenged mice.
- Published
- 2006
- Full Text
- View/download PDF
7. Rhinovirus infection induces cytotoxicity and delays wound healing in bronchial epithelial cells
- Author
-
Constantopoulos Andreas G, Skevaki Chrysanthi L, Gourgiotis Dimitrios, Psarras Stelios, Bossios Apostolos, Saxoni-Papageorgiou Photini, and Papadopoulos Nikolaos G
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Human rhinoviruses (RV), the most common triggers of acute asthma exacerbations, are considered not cytotoxic to the bronchial epithelium. Recent observations, however, have questioned this knowledge. The aim of this study was to evaluate the ability of RV to induce epithelial cytotoxicity and affect epithelial repair in-vitro. Methods Monolayers of BEAS-2B bronchial epithelial cells, seeded at different densities were exposed to RV serotypes 1b, 5, 7, 9, 14, 16. Cytotoxicity was assessed chromatometrically. Epithelial monolayers were mechanically wounded, exposed or not to RV and the repopulation of the damaged area was assessed by image analysis. Finally epithelial cell proliferation was assessed by quantitation of proliferating cell nuclear antigen (PCNA) by flow cytometry. Results RV1b, RV5, RV7, RV14 and RV16 were able to induce considerable epithelial cytotoxicity, more pronounced in less dense cultures, in a cell-density and dose-dependent manner. RV9 was not cytotoxic. Furthermore, RV infection diminished the self-repair capacity of bronchial epithelial cells and reduced cell proliferation. Conclusion RV-induced epithelial cytotoxicity may become considerable in already compromised epithelium, such as in the case of asthma. The RV-induced impairment on epithelial proliferation and self-repair capacity may contribute to the development of airway remodeling.
- Published
- 2005
- Full Text
- View/download PDF
8. Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9
- Author
-
Johansson Anna-Karin, Bossios Apostolos, Rådinger Madeleine, Sitkauskiene Brigita, Sakalauskas Raimundas, and Lötvall Jan
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Interleukin (IL)-9 is a Th2-derived cytokine with pleiotropic biological effects, which recently has been proposed as a candidate gene for asthma and allergy. We aimed to evaluate the therapeutic effect of a neutralizing anti-IL-9 antibody in a mouse model of airway eosinophilic inflammation and compared any such effect with anti-IL-5 treatment. Methods OVA-sensitized Balb/c mice were intraperitoneally pretreated with a single dose (100 μg) of an anti-mouse IL-9 monoclonal antibody (clone D9302C12) or its vehicle. A third group was given 50 μg of a monoclonal anti-mouse IL-5 antibody (TRFK-5) or its vehicle. Animals were subsequently exposed to OVA on five days via airways. Newly produced eosinophils were labelled using 5-bromo-2'-deoxyuridine (BrdU). BrdU+ eosinophils and CD34+ cell numbers were examined by immunocytochemistry. After culture and stimulation with OVA or PMA+IC, intracellular staining of IL-9 in bone marrow cells from OVA-exposed animals was measured by Flow Cytometry. The Mann-Whitney U-test was used to determine significant differences between groups. Results Anti-IL-9 significantly reduced bone marrow eosinophilia, primarily by decrease of newly produced (BrdU+) and mature eosinophils. Anti-IL-9 treatment also reduced blood neutrophil counts, but did not affect BAL neutrophils. Anti-IL-5 was able to reduce eosinophil numbers in all tissue compartments, as well as BrdU+ eosinophils and CD34+ progenitor cells, and in all instances to a greater extent than anti-IL-9. Also, FACS analysis showed that IL-9 is over-expressed in bone marrow CD4+ cells after allergen exposure. Conclusions Our data shows that a single dose of a neutralizing IL-9 antibody is not sufficient to reduce allergen-induced influx of newly produced cells from bone marrow to airways. However, in response to allergen, bone marrow cells over-express IL-9. This data suggest that IL-9 may participate in the regulation of granulocytopoiesis in allergic inflammation.
- Published
- 2005
- Full Text
- View/download PDF
9. Treatable traits and exacerbation risk in patients with uncontrolled asthma prescribed GINA step 1–3 treatment: A nationwide asthma cohort study
- Author
-
Konradsen, Jon R., primary, Selberg, Stina, additional, Ödling, Maria, additional, Sundbaum, Johanna Karlsson, additional, Bossios, Apostolos, additional, and Stridsman, Caroline, additional
- Published
- 2024
- Full Text
- View/download PDF
10. Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
- Author
-
Spinou, Arietta, primary, Hererro-Cortina, Beatriz, additional, Aliberti, Stefano, additional, Goeminne, Pieter C, additional, Polverino, Eva, additional, Dimakou, Katerina, additional, Haworth, Charles S, additional, Loebinger, Michael R, additional, De Soyza, Anthony, additional, Vendrell, Montserrat, additional, Burgel, Pierre Regis, additional, McDonnell, Melissa, additional, Sutharsan, Sivagurunathan, additional, Skrgat, Sabina, additional, Maiz-Carro, Luiz, additional, Sibila, Oriol, additional, Stolz, Daiana, additional, Kauppi, Paula, additional, Bossios, Apostolos, additional, Hill, Adam T, additional, Clifton, Ian, additional, Crichton, Megan L, additional, Walker, Paul, additional, Menendez, Rosario, additional, Borecki, Sermin, additional, Obradovic, Dusanka, additional, Nowinski, Adam, additional, Amorim, Adelina, additional, Torres, Antoni, additional, Lorent, Natalie, additional, Welte, Tobias, additional, Blasi, Francesco, additional, Makek, Mateja Jankovic, additional, Shteinberg, Michal, additional, Boersma, Wim, additional, Elborn, J Stuart, additional, Chalmers, James D, additional, and Ringshausen, Felix C, additional
- Published
- 2024
- Full Text
- View/download PDF
11. The interplay between obesity and blood neutrophils in adult-onset asthma
- Author
-
Backman, Helena, Winsa-Lindmark, Sofia, Hedman, Linnea, Kankaanranta, Hannu, Warm, Katja, Lindberg, Anne, Bossios, Apostolos, Rönmark, Eva, Stridsman, Caroline, Backman, Helena, Winsa-Lindmark, Sofia, Hedman, Linnea, Kankaanranta, Hannu, Warm, Katja, Lindberg, Anne, Bossios, Apostolos, Rönmark, Eva, and Stridsman, Caroline
- Abstract
Highlights: Severe obesity strongly associates to blood neutrophils in adult-onset asthma. B-neutrophils may partly mediate associations between obesity and asthma control. Clinical evaluation of adult-onset asthma should include assessing B-neutrophils.
- Published
- 2024
- Full Text
- View/download PDF
12. Treatable traits and exacerbation risk in patients with uncontrolled asthma prescribed GINA step 1–3 treatment : a nationwide asthma cohort study
- Author
-
Konradsen, Jon R., Selberg, Stina, Ödling, Maria, Sundbaum, Johanna Karlsson, Bossios, Apostolos, Stridsman, Caroline, Konradsen, Jon R., Selberg, Stina, Ödling, Maria, Sundbaum, Johanna Karlsson, Bossios, Apostolos, and Stridsman, Caroline
- Abstract
Background and Objective: Uncontrolled asthma in patients treated for mild/moderate disease could be caused by non-pulmonary treatable traits (TTs) that affect asthma control negatively. We aimed to identify demographic characteristics, behavioural (smoking) and extrapulmonary (obesity, comorbidities) TTs and the risk for future exacerbations among patients with uncontrolled asthma prescribed step 1–3 treatment according to the Global Initiative for Asthma (GINA). Methods: Twenty-eight thousand five hundred eighty-four asthma patients (≥18 y) with a registration in the Swedish National Airway Register between 2017 and 2019 were included (index-date). The database was linked to other national registers to obtain information on prescribed drugs 2-years pre-index and exacerbations 1-year post-index. Asthma treatment was classified into step 1–3 or 4–5, and uncontrolled asthma was defined based on symptom control, exacerbations and lung function. Results: GINA step 1–3 included 17,318 patients, of which 9586 (55%) were uncontrolled (UCA 1–3). In adjusted analyses, UCA 1–3 was associated with female sex (OR 1.34, 95% CI 1.27–1.41), older age (1.00, 1.00–1.00), primary education (1.30, 1.20–1.40) and secondary education (1.19, 1.12–1.26), and TTs such as smoking (1.25, 1.15–1.36), obesity (1.23, 1.15–1.32), cardiovascular disease (1.12, 1.06–1.20) and depression/anxiety (1.13, 1.06–1.21). Furthermore, UCA 1–3 was associated with future exacerbations; oral corticosteroids (1.90, 1.74–2.09) and asthma hospitalization (2.55, 2.17–3.00), respectively, also when adjusted for treatment step 4–5. Conclusion: Over 50% of patients treated for mild/moderate asthma had an uncontrolled disease. Assessing and managing of TTs such as smoking, obesity and comorbidities should be conducted in a holistic manner, as these patients have an increased risk for future exacerbations.
- Published
- 2024
- Full Text
- View/download PDF
13. ERS International Congress 2023:highlights from the Airway Diseases Assembly
- Author
-
Bergantini, Laura, Baker, James, Bossios, Apostolos, Braunstahl, Gert Jan, Conemans, Lennart H., Lombardi, Francesco, Mathioudakis, Alexander G., Pobeha, Pavol, Ricciardolo, Fabio Luigi Massimo, Romero, Leidy Paola Prada, Schleich, Florence, Snelgrove, Robert J., Trinkmann, Frederik, Uller, Lena, Beech, Augusta, Bergantini, Laura, Baker, James, Bossios, Apostolos, Braunstahl, Gert Jan, Conemans, Lennart H., Lombardi, Francesco, Mathioudakis, Alexander G., Pobeha, Pavol, Ricciardolo, Fabio Luigi Massimo, Romero, Leidy Paola Prada, Schleich, Florence, Snelgrove, Robert J., Trinkmann, Frederik, Uller, Lena, and Beech, Augusta
- Abstract
In this review, early career and senior members of Assembly 5 (Airway Diseases, Asthma, COPD and Chronic Cough) present key recent findings pertinent to airway diseases that were presented during the European Respiratory Society International Congress 2023 in Milan, Italy, with a particular focus on asthma, COPD, chronic cough and bronchiectasis. During the congress, an increased number of symposia, workshops and abstract presentations were organised. In total, 739 abstracts were submitted for Assembly 5 and the majority of these were presented by early career members. These data highlight the increased interest in this group of respiratory diseases.
- Published
- 2024
14. Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
- Author
-
Aliberti, Stefano, Ringshausen, Felix C., Dhar, Raja, Haworth, Charles S., Loebinger, Michael R., Dimakou, Katerina, Crichton, Megan L., De Soyza, Anthony, Vendrell, Montse, Burgel, Pierre-Regis, McDonnell, Melissa, Skrgat, Sabina, Maiz Carro, Luis, de Roux, Andres, Sibila, Oriol, Bossios, Apostolos, van der Eerden, Menno, Kauppi, Paula, Wilson, Robert, Milenkovic, Branislava, Menendez, Rosario, Murris, Marlene, Borekci, Sermin, Munteanu, Oxana, Obradovic, Dusanka, Nowinski, Adam, Amorim, Adelina, Torres, Antoni, Lorent, Natalie, Van Braeckel, Eva, Altenburg, Josje, Shoemark, Amelia, Shteinberg, Michal, Boersma, Wim, Goeminne, Pieter C., Elborn, J. Stuart, Hill, Adam T., Welte, Tobias, Blasi, Francesco, Polverino, Eva, Chalmers, James D., Aliberti, Stefano, Ringshausen, Felix C., Dhar, Raja, Haworth, Charles S., Loebinger, Michael R., Dimakou, Katerina, Crichton, Megan L., De Soyza, Anthony, Vendrell, Montse, Burgel, Pierre-Regis, McDonnell, Melissa, Skrgat, Sabina, Maiz Carro, Luis, de Roux, Andres, Sibila, Oriol, Bossios, Apostolos, van der Eerden, Menno, Kauppi, Paula, Wilson, Robert, Milenkovic, Branislava, Menendez, Rosario, Murris, Marlene, Borekci, Sermin, Munteanu, Oxana, Obradovic, Dusanka, Nowinski, Adam, Amorim, Adelina, Torres, Antoni, Lorent, Natalie, Van Braeckel, Eva, Altenburg, Josje, Shoemark, Amelia, Shteinberg, Michal, Boersma, Wim, Goeminne, Pieter C., Elborn, J. Stuart, Hill, Adam T., Welte, Tobias, Blasi, Francesco, Polverino, Eva, and Chalmers, James D.
- Abstract
Background A validated 4-point sputum colour chart can be used to objectively evaluate the levels of airway inflammation in bronchiectasis patients. In the European Bronchiectasis Registry (EMBARC), we tested whether sputum colour would be associated with disease severity and clinical outcomes. Methods We used a prospective, observational registry of adults with bronchiectasis conducted in 31 countries. Patients who did not produce spontaneous sputum were excluded from the analysis. The Murray sputum colour chart was used at baseline and at follow-up visits. Key outcomes were frequency of exacerbations, hospitalisations for severe exacerbations and mortality during up to 5-year follow-up. Results 13 484 patients were included in the analysis. More purulent sputum was associated with lower forced expiratory volume in 1 s (FEV 1), worse quality of life, greater bacterial infection and a higher bronchiectasis severity index. Sputum colour was strongly associated with the risk of future exacerbations during follow-up. Compared to patients with mucoid sputum (reference group), patients with mucopurulent sputum experienced significantly more exacerbations (incident rate ratio (IRR) 1.29, 95% CI 1.22–1.38; p<0.0001), while the rates were even higher for patients with purulent (IRR 1.55, 95% CI 1.44–1.67; p<0.0001) and severely purulent sputum (IRR 1.91, 95% CI 1.52–2.39; p<0.0001). Hospitalisations for severe exacerbations were also associated with increasing sputum colour with rate ratios, compared to patients with mucoid sputum, of 1.41 (95% CI 1.29–1.56; p<0.0001), 1.98 (95% CI 1.77–2.21; p<0.0001) and 3.05 (95% CI 2.25–4.14; p<0.0001) for mucopurulent, purulent and severely purulent sputum, respectively. Mortality was significantly increased with increasing sputum purulence, hazard ratio 1.12 (95% CI 1.01–1.24; p=0.027), for each increment in sputum purulence. Conclusion Sputum colour is a simple marker of disease severity and future ris
- Published
- 2024
15. Small airways disease in chronic obstructive pulmonary disease.
- Author
-
Lazarinis, Nikolaos, Fouka, Evangelia, Linden, Anders, and Bossios, Apostolos
- Published
- 2024
- Full Text
- View/download PDF
16. The Association between Bronchiectasis and Chronic Obstructive Pulmonary Disease: Data from the European Bronchiectasis Registry (EMBARC).
- Author
-
Polverino, Eva, De Soyza, Anthony, Dimakou, Katerina, Traversi, Letizia, Bossios, Apostolos, Crichton, Megan L., Ringshausen, Felix C., Vendrell, Montserrat, Burgel, Pierre-Régis, Haworth, Charles S., Loebinger, Michael R., Lorent, Natalie, Pink, Isabell, McDonnell, Melissa, Skrgat, Sabina, Carro, Luis M., Sibila, Oriol, van der Eerden, Menno, Kauppi, Paula, and Shoemark, Amelia
- Subjects
BRONCHIECTASIS ,CHRONIC obstructive pulmonary disease - Abstract
Rationale: COPD and bronchiectasis are commonly reported together. Studies report varying impacts of co-diagnosis on outcomes, which may be related to different definitions of disease used across studies. Objectives: To investigate the prevalence of chronic obstructive pulmonary disease (COPD) associated with bronchiectasis and its relationship with clinical outcomes. We further investigated the impact of implementing the standardized ROSE criteria (radiological bronchiectasis [R], obstruction [FEV
1 /FVC ratio <0.7; O], symptoms [S], and exposure [⩾10 pack-years of smoking; E]), an objective definition of the association of bronchiectasis with COPD. Methods: Analysis of the EMBARC (European Bronchiectasis Registry), a prospective observational study of patients with computed tomography–confirmed bronchiectasis from 28 countries. The ROSE criteria were used to objectively define the association of bronchiectasis with COPD. Key outcomes during a maximum of 5 years of follow-up were exacerbations, hospitalization, and mortality. Measurements and Main Results: A total of 16,730 patients with bronchiectasis were included; 4,336 had a clinician-assigned codiagnosis of COPD, and these patients had more exacerbations, worse quality of life, and higher severity scores. We observed marked overdiagnosis of COPD: 22.2% of patients with a diagnosis of COPD did not have airflow obstruction and 31.9% did not have a history of ⩾10 pack-years of smoking. Therefore, 2,157 patients (55.4%) met the ROSE criteria for COPD. Compared with patients without COPD, patients who met the ROSE criteria had increased risks of exacerbations and exacerbations resulting in hospitalization during follow-up (incidence rate ratio, 1.25; 95% confidence interval, 1.15–1.35; vs. incidence rate ratio, 1.69; 95% confidence interval, 1.51–1.90, respectively). Conclusions: The label of COPD is often applied to patients with bronchiectasis who do not have objective evidence of airflow obstruction or a smoking history. Patients with a clinical label of COPD have worse clinical outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
17. Adherence to Inhaled Corticosteroid Therapy and Treatment Escalation in the Swedish Adult Asthma Population
- Author
-
Packham, Sylvia, primary, Ödling, Maria, additional, Bossios, Apostolos, additional, Konradsen, Jon R., additional, and Stridsman, Caroline, additional
- Published
- 2024
- Full Text
- View/download PDF
18. COVID-19 vaccination, acceptance, safety, and side-effects in European patients with severe asthma
- Author
-
Bossios, Apostolos, primary, Bacon, Alison M., additional, Eger, Katrien, additional, Paróczai, Dóra, additional, Schleich, Florence, additional, Hanon, Shane, additional, Sergejeva, Svetlana, additional, Zervas, Eleftherios, additional, Katsoulis, Konstantinos, additional, Aggelopoulou, Christina, additional, Kostikas, Konstantinos, additional, Gaki, Eleni, additional, Rovina, Nikoletta, additional, Csoma, Zsuzsanna, additional, Grisle, Ineta, additional, Bieksiené, Kristina, additional, Palacionyte, Jolita, additional, ten Brinke, Anneke, additional, Hashimoto, Simone, additional, Mihălţan, Florin, additional, Nenasheva, Natalia, additional, Zvezdin, Biljana, additional, Čekerevac, Ivan, additional, Hromiš, Sanja, additional, Ćupurdija, Vojislav, additional, Lazic, Zorica, additional, Chaudhuri, Rekha, additional, Smith, Steven James, additional, Rupani, Hitasha, additional, Haitchi, Hans Michael, additional, Kurukulaaratchy, Ramesh, additional, Fulton, Olivia, additional, Frankemölle, Betty, additional, Howarth, Peter, additional, Porsbjerg, Celeste, additional, Bel, Elisabeth H., additional, Djukanovic, Ratko, additional, and Hyland, Michael E., additional
- Published
- 2023
- Full Text
- View/download PDF
19. ERS International Congress 2023: highlights from the Airway Diseases Assembly.
- Author
-
Bergantini, Laura, Baker, James, Bossios, Apostolos, Braunstahl, Gert-Jan, Conemans, Lennart H., Lombardi, Francesco, Mathioudakis, Alexander G., Pobeha, Pavol, Massimo Ricciardolo, Fabio Luigi, Prada Romero, Leidy Paola, Schleich, Florence, Snelgrove, Robert J., Trinkmann, Frederik, Uller, Lena, and Beech, Augusta
- Published
- 2024
- Full Text
- View/download PDF
20. Changes of QoL-B in bronchiectasis patients undergoing an outpatient intravenous antibiotic therapy; preliminary results from a tertiary European Multicenter Bronchiectasis Audit and Research Collaboration (EMBARC) centre.
- Author
-
Ghosh, Pia, primary, Sande, Malin, additional, Chalmers, James D., additional, and Bossios, Apostolos, additional
- Published
- 2023
- Full Text
- View/download PDF
21. Under-treated asthma in adults – a common problem
- Author
-
Konradsen, Jon R, primary, Selberg, Stina, additional, Ödling, Maria, additional, Bossios, Apostolos, additional, and Stridsman, Caroline, additional
- Published
- 2023
- Full Text
- View/download PDF
22. Small airways impairment and hyperinflation in patients with bronchiectasis; preliminary data from a tertiary center.
- Author
-
Lazarinis, Nikolaos, primary, Ghosh, Pia, additional, Sande, Malin, additional, Lantz, Ann Sofie, additional, Wallen Nielsen, Eva, additional, Dahlen, Barbro, additional, and Bossios, Apostolos, additional
- Published
- 2023
- Full Text
- View/download PDF
23. Allergic inflammation modulates the adiponectin/adiponectin receptor 1 axis in lung regulatory T cells in vivo
- Author
-
Ramos-Ramírez, Patricia, primary, Malmhäll, Carina, additional, and Bossios, Apostolos, additional
- Published
- 2023
- Full Text
- View/download PDF
24. Severe asthma trajectories in adults: findings from the NORDSTAR cohort
- Author
-
von Bülow, Anna, primary, Hansen, Susanne, additional, Sandin, Patrik, additional, Ernstsson, Olivia, additional, Janson, Christer, additional, Lehtimäki, Lauri, additional, Kankaanranta, Hannu, additional, Ulrik, Charlotte, additional, Aarli, Bernt Bøgvald, additional, Geale, Kirk, additional, Tang, Sheila Tuyet, additional, Wolf, Maija, additional, Backer, Vibeke, additional, Hilberg, Ole, additional, Altraja, Alan, additional, Backman, Helena, additional, Lúdvíksdóttir, Dóra, additional, Björnsdóttir, Unnur Steina, additional, Kauppi, Paula, additional, Sandström, Thomas, additional, Sverrild, Asger, additional, Yasinska, Valentyna, additional, Kilpeläinen, Maritta, additional, Dahlén, Barbro, additional, Viinanen, Arja, additional, Bjermer, Leif, additional, Bossios, Apostolos, additional, and Porsbjerg, Celeste, additional
- Published
- 2023
- Full Text
- View/download PDF
25. Editorial: Exploring the role of adaptive immunity in chronic airway respiratory diseases.
- Author
-
Fouka, Evangelia, Bossios, Apostolos, Steiropoulos, Paschalis, and Samitas, Konstantinos
- Published
- 2024
- Full Text
- View/download PDF
26. Research highlights from the 2022 European Respiratory Society International Congress: Airway diseases
- Author
-
Beech, Augusta, primary, Portacci, Andrea, additional, Herrero-Cortina, Beatrice, additional, Mathioudakis, Alexander G., additional, Gotera, Carolina, additional, Uller, Lena, additional, Ricciardolo, Fabio Luigi Massimo, additional, Pobeha, Pavol, additional, Snelgrove, Robert J., additional, Braunstahl, Gert-Jan, additional, Bossios, Apostolos, additional, Usmani, Omar, additional, and Ananth, Sachin, additional
- Published
- 2023
- Full Text
- View/download PDF
27. Prevalence and management of severe asthma in the Nordic countries: findings from the NORDSTAR cohort
- Author
-
Hansen, Susanne, primary, von Bülow, Anna, additional, Sandin, Patrik, additional, Ernstsson, Olivia, additional, Janson, Christer, additional, Lehtimäki, Lauri, additional, Kankaanranta, Hannu, additional, Ulrik, Charlotte, additional, Aarli, Bernt Bøgvald, additional, Fues Wahl, Hanna, additional, Geale, Kirk, additional, Tang, Sheila Tuyet, additional, Wolf, Maija, additional, Larsen, Tom, additional, Altraja, Alan, additional, Backman, Helena, additional, Kilpeläinen, Maritta, additional, Viinanen, Arja, additional, Ludviksdottir, Dora, additional, Kauppi, Paula, additional, Sverrild, Asger, additional, Lehmann, Sverre, additional, Backer, Vibeke, additional, Yasinska, Valentyna, additional, Skjold, Tina, additional, Karjalainen, Jussi, additional, Bossios, Apostolos, additional, and Porsbjerg, Celeste, additional
- Published
- 2023
- Full Text
- View/download PDF
28. Prevalence and management of severe asthma in the Nordic countries : findings from the NORDSTAR cohort
- Author
-
Hansen, Susanne, von Bulow, Anna, Sandin, Patrik, Ernstsson, Olivia, Janson, Christer, Lehtimaki, Lauri, Kankaanranta, Hannu, Ulrik, Charlotte, Aarli, Bernt Bogvald, Wahl, Hanna Fues, Geale, Kirk, Tang, Sheila Tuyet, Wolf, Maija, Larsen, Tom, Altraja, Alan, Backman, Helena, Kilpelainen, Maritta, Viinanen, Arja, Ludviksdottir, Dora, Kauppi, Paula, Sverrild, Asger, Lehmann, Sverre, Backer, Vibeke, Yasinska, Valentyna, Skjold, Tina, Karjalainen, Jussi, Bossios, Apostolos, Porsbjerg, Celeste, Hansen, Susanne, von Bulow, Anna, Sandin, Patrik, Ernstsson, Olivia, Janson, Christer, Lehtimaki, Lauri, Kankaanranta, Hannu, Ulrik, Charlotte, Aarli, Bernt Bogvald, Wahl, Hanna Fues, Geale, Kirk, Tang, Sheila Tuyet, Wolf, Maija, Larsen, Tom, Altraja, Alan, Backman, Helena, Kilpelainen, Maritta, Viinanen, Arja, Ludviksdottir, Dora, Kauppi, Paula, Sverrild, Asger, Lehmann, Sverre, Backer, Vibeke, Yasinska, Valentyna, Skjold, Tina, Karjalainen, Jussi, Bossios, Apostolos, and Porsbjerg, Celeste
- Abstract
Background: Real-life evidence on prevalence and management of severe asthma is limited. Nationwide population registries across the Nordic countries provide unique opportunities to describe prevalence and management patterns of severe asthma at population level. In nationwide register data from Sweden, Norway and Finland, we examined the prevalence of severe asthma and the proportion of severe asthma patients being managed in specialist care. Methods: This is a cross-sectional study based on the Nordic Dataset for Asthma Research (NORDSTAR) research collaboration platform. We identified patients with severe asthma in adults (aged >= 18 years) and in children (aged 6-17 years) in 2018 according to the European Respiratory Society/American Thoracic Society definition. Patients managed in specialist care were those with an asthma-related specialist outpatient contact (only available in Sweden and Finland). Results: Overall, we identified 598 242 patients with current asthma in Sweden, Norway and Finland in 2018. Among those, the prevalence of severe asthma was 3.5%, 5.4% and 5.2% in adults and 0.4%, 1.0%, and 0.3% in children in Sweden, Norway and Finland, respectively. In Sweden and Finland, 37% and 40% of adult patients with severe asthma and two or more exacerbations, respectively, were managed in specialist care; in children the numbers were 56% and 41%, respectively. Conclusion: In three Nordic countries, population-based nationwide data demonstrated similar prevalence of severe asthma. In children, severe asthma was a rare condition. Notably, a large proportion of patients with severe asthma were not managed by a respiratory specialist, suggesting the need for increased recognition of severe asthma in primary care.
- Published
- 2023
- Full Text
- View/download PDF
29. Severe asthma trajectories in adults : findings from the NORDSTAR cohort
- Author
-
von Bülow, Anna, Hansen, Susanne, Sandin, Patrik, Ernstsson, Olivia, Janson, Christer, Lehtimäki, Lauri, Kankaanranta, Hannu, Ulrik, Charlotte, Aarli, Bernt Bøgvald, Geale, Kirk, Tang, Sheila Tuyet, Wolf, Maija, Backer, Vibeke, Hilberg, Ole, Altraja, Alan, Backman, Helena, Lúdvíksdóttir, Dóra, Björnsdóttir, Unnur Steina, Kauppi, Paula, Sandström, Thomas, Sverrild, Asger, Yasinska, Valentyna, Kilpeläinen, Maritta, Dahlén, Barbro, Viinanen, Arja, Bjermer, Leif, Bossios, Apostolos, Porsbjerg, Celeste, von Bülow, Anna, Hansen, Susanne, Sandin, Patrik, Ernstsson, Olivia, Janson, Christer, Lehtimäki, Lauri, Kankaanranta, Hannu, Ulrik, Charlotte, Aarli, Bernt Bøgvald, Geale, Kirk, Tang, Sheila Tuyet, Wolf, Maija, Backer, Vibeke, Hilberg, Ole, Altraja, Alan, Backman, Helena, Lúdvíksdóttir, Dóra, Björnsdóttir, Unnur Steina, Kauppi, Paula, Sandström, Thomas, Sverrild, Asger, Yasinska, Valentyna, Kilpeläinen, Maritta, Dahlén, Barbro, Viinanen, Arja, Bjermer, Leif, Bossios, Apostolos, and Porsbjerg, Celeste
- Abstract
Background: There is limited evidence on the pathways leading to severe asthma and we are presently unable to effectively predict the progression of the disease. We aimed to describe the longitudinal trajectories leading to severe asthma and to describe clinical events preceding disease progression in a nationwide population of patients with severe asthma. Methods: We conducted an observational study based on Swedish data from the NORdic Dataset for aSThmA Research (NORDSTAR) research collaboration platform. We identified adult patients with severe asthma in 2018 according to the European Respiratory Society/American Thoracic Society definition and used latent class analysis to identify trajectories of asthma severity over a 10-year retrospective period from 2018. Results: Among 169 128 asthma patients, we identified 4543 severe asthma patients. We identified four trajectories of severe asthma that were labelled as: trajectory 1 "consistently severe asthma" (n=389 (8.6%)), trajectory 2 "gradual onset severe asthma" (n=942 (20.7%)), trajectory 3 "intermittent severe asthma" (n=1685 (37.1%)) and trajectory 4 "sudden onset severe asthma" (n=1527 (33.6%)). "Consistently severe asthma" had a higher daily inhaled corticosteroid dose and more prevalent osteoporosis compared with the other trajectories. Patients with "gradual onset severe asthma" and "sudden onset severe asthma" developed type 2-related comorbidities concomitantly with development of severe asthma. In the latter group, this primarily occurred within 1-3 years preceding onset of severe asthma. Conclusions: Four distinct trajectories of severe asthma were identified illustrating different patterns of progression of asthma severity. This may eventually enable the development of better preventive management strategies in severe asthma.
- Published
- 2023
- Full Text
- View/download PDF
30. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)
- Author
-
Khaleva, Ekaterina, Rattu, Anna, Brightling, Chris, Bush, Andrew, Bossios, Apostolos, Bourdin, Arnaud, Chung, Kian Fan, Chaudhuri, Rekha, Coleman, Courtney, Dahlén, Sven Erik, Djukanovic, Ratko, Deschildre, Antoine, Fleming, Louise, Fowler, Stephen J., Gupta, Atul, Hamelmann, Eckard, Hashimoto, Simone, Hedlin, Gunilla, Koppelman, Gerard H., Melén, Erik, Murray, Clare S., Pilette, Charles, Porsbjerg, Celeste, Pike, Katharine C., Rusconi, Franca, Williams, Clare, Ahrens, Birgit, Alter, Peter, Anckers, Freja, van den Berge, Maarten, Blumchen, Katharina, Brusselle, Guy, Clarke, Graham W., Cunoosamy, Danen, Dahlén, Barbro, Dixey, Piers, Exley, Andrew, Frey, Urs, Gaillard, Erol A., Giovannini-Chami, Lisa, Grigg, Jonathan, Hartenstein, Diana, Heaney, Liam G., Karadag, Bülent, Kaul, Susanne, Kull, Inger, Licari, Amelia, Maitland-van der Zee, Anke-Hilse, Mahler, Vera, Schoos, Ann Marie M., Nagakumar, Prasad, Negus, Jenny, Nielsen, Hanna, Pijnenburg, Mariëlle, Ramiconi, Valeria, Romagosa Vilarnau, Sofia, Principe, Stefania, Rutjes, Niels W. P., Saglani, Sejal, Seddon, Paul C, Singer, Florian, Staudinger, Heribert, Turner, Steve, Vijverberg, Susanne J, Winders, Tonya, Yasinska, Valentyna, Roberts, Graham, Sverrild, Asger, Lapperre, Therese, Khaleva, Ekaterina, Rattu, Anna, Brightling, Chris, Bush, Andrew, Bossios, Apostolos, Bourdin, Arnaud, Chung, Kian Fan, Chaudhuri, Rekha, Coleman, Courtney, Dahlén, Sven Erik, Djukanovic, Ratko, Deschildre, Antoine, Fleming, Louise, Fowler, Stephen J., Gupta, Atul, Hamelmann, Eckard, Hashimoto, Simone, Hedlin, Gunilla, Koppelman, Gerard H., Melén, Erik, Murray, Clare S., Pilette, Charles, Porsbjerg, Celeste, Pike, Katharine C., Rusconi, Franca, Williams, Clare, Ahrens, Birgit, Alter, Peter, Anckers, Freja, van den Berge, Maarten, Blumchen, Katharina, Brusselle, Guy, Clarke, Graham W., Cunoosamy, Danen, Dahlén, Barbro, Dixey, Piers, Exley, Andrew, Frey, Urs, Gaillard, Erol A., Giovannini-Chami, Lisa, Grigg, Jonathan, Hartenstein, Diana, Heaney, Liam G., Karadag, Bülent, Kaul, Susanne, Kull, Inger, Licari, Amelia, Maitland-van der Zee, Anke-Hilse, Mahler, Vera, Schoos, Ann Marie M., Nagakumar, Prasad, Negus, Jenny, Nielsen, Hanna, Pijnenburg, Mariëlle, Ramiconi, Valeria, Romagosa Vilarnau, Sofia, Principe, Stefania, Rutjes, Niels W. P., Saglani, Sejal, Seddon, Paul C, Singer, Florian, Staudinger, Heribert, Turner, Steve, Vijverberg, Susanne J, Winders, Tonya, Yasinska, Valentyna, Roberts, Graham, Sverrild, Asger, and Lapperre, Therese
- Abstract
Background Effectiveness studies with biological therapies for asthma lack standardised outcome measures. The COMSA (Core Outcome Measures sets for paediatric and adult Severe Asthma) Working Group sought to develop Core Outcome Measures (COM) sets to facilitate better synthesis of data and appraisal of biologics in paediatric and adult asthma clinical studies. Methods COMSA utilised a multi-stakeholder consensus process among patients with severe asthma, adult and paediatric clinicians, pharmaceutical representatives, and health regulators from across Europe. Evidence included a systematic review of development, validity and reliability of selected outcome measures plus a narrative review and a pan-European survey to better understand patients’ and carers’ views about outcome measures. It was discussed using a modified GRADE (Grading of Recommendations Assessment, Development and Evaluation) Evidence to Decision framework. Anonymous voting was conducted using predefined consensus criteria. Results Both adult and paediatric COM sets include forced expiratory volume in 1 s (FEV1) as z-scores, annual frequency of severe exacerbations and maintenance oral corticosteroid use. Additionally, the paediatric COM set includes the Paediatric Asthma Quality of Life Questionnaire and Asthma Control Test or Childhood Asthma Control Test, while the adult COM set includes the Severe Asthma Questionnaire and Asthma Control Questionnaire-6 (symptoms and rescue medication use reported separately). Conclusions This patient-centred collaboration has produced two COM sets for paediatric and adult severe asthma. It is expected that they will inform the methodology of future clinical trials, enhance comparability of efficacy and effectiveness of biological therapies, and help assess their socioeconomic value. COMSA will inform definitions of non-response and response to biological therapy for severe asthma., Background Effectiveness studies with biological therapies for asthma lack standardised outcome measures. The COMSA (Core Outcome Measures sets for paediatric and adult Severe Asthma) Working Group sought to develop Core Outcome Measures (COM) sets to facilitate better synthesis of data and appraisal of biologics in paediatric and adult asthma clinical studies. Methods COMSA utilised a multi-stakeholder consensus process among patients with severe asthma, adult and paediatric clinicians, pharmaceutical representatives, and health regulators from across Europe. Evidence included a systematic review of development, validity and reliability of selected outcome measures plus a narrative review and a pan-European survey to better understand patients’ and carers’ views about outcome measures. It was discussed using a modified GRADE (Grading of Recommendations Assessment, Development and Evaluation) Evidence to Decision framework. Anonymous voting was conducted using predefined consensus criteria. Results Both adult and paediatric COM sets include forced expiratory volume in 1 s (FEV1) as z-scores, annual frequency of severe exacerbations and maintenance oral corticosteroid use. Additionally, the paediatric COM set includes the Paediatric Asthma Quality of Life Questionnaire and Asthma Control Test or Childhood Asthma Control Test, while the adult COM set includes the Severe Asthma Questionnaire and Asthma Control Questionnaire-6 (symptoms and rescue medication use reported separately). Conclusions This patient-centred collaboration has produced two COM sets for paediatric and adult severe asthma. It is expected that they will inform the methodology of future clinical trials, enhance comparability of efficacy and effectiveness of biological therapies, and help assess their socioeconomic value. COMSA will inform definitions of non-response and response to biological therapy for severe asthma.
- Published
- 2023
31. Definitions of non-response and response to biological therapy for severe asthma: a systematic review
- Author
-
Khaleva, Ekaterina, primary, Rattu, Anna, additional, Brightling, Chris, additional, Bush, Andrew, additional, Bourdin, Arnaud, additional, Bossios, Apostolos, additional, Chung, Kian Fan, additional, Chaudhuri, Rekha, additional, Coleman, Courtney, additional, Djukanovic, Ratko, additional, Dahlén, Sven-Erik, additional, Exley, Andrew, additional, Fleming, Louise, additional, Fowler, Stephen J., additional, Gupta, Atul, additional, Hamelmann, Eckard, additional, Koppelman, Gerard H., additional, Melén, Erik, additional, Mahler, Vera, additional, Seddon, Paul, additional, Singer, Florian, additional, Porsbjerg, Celeste, additional, Ramiconi, Valeria, additional, Rusconi, Franca, additional, Yasinska, Valentyna, additional, and Roberts, Graham, additional
- Published
- 2023
- Full Text
- View/download PDF
32. Identifying and appraising outcome measures for severe asthma: a systematic review
- Author
-
Rattu, Anna, primary, Khaleva, Ekaterina, additional, Brightling, Chris, additional, Dahlén, Sven-Erik, additional, Bossios, Apostolos, additional, Fleming, Louise, additional, Chung, Kian Fan, additional, Melén, Erik, additional, Djukanovic, Ratko, additional, Chaudhuri, Rekha, additional, Exley, Andrew, additional, Koppelman, Gerard H., additional, Bourdin, Arnaud, additional, Rusconi, Franca, additional, Porsbjerg, Celeste, additional, Coleman, Courtney, additional, Williams, Clare, additional, Nielsen, Hanna, additional, Davin, Elizabeth, additional, Taverner, Phil, additional, Romagosa Vilarnau, Sofia, additional, and Roberts, Graham, additional
- Published
- 2022
- Full Text
- View/download PDF
33. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)
- Author
-
Khaleva, Ekaterina, Rattu, Anna, Brightling, Chris, Bush, Andrew, Bossios, Apostolos, Bourdin, Arnaud, Chung, Kian Fan, Chaudhuri, Rekha, Coleman, Courtney, Dahlén, Sven-Erik, Djukanovic, Ratko, Deschildre, Antoine, Fleming, Louise, Fowler, Stephen J, Gupta, Atul, Hamelmann, Eckard, Hashimoto, Simone, Hedlin, Gunilla, Koppelman, Gerard H, Melén, Erik, Murray, Clare S, Pilette, Charles, Porsbjerg, Celeste, Pike, Katharine C, Rusconi, Franca, Williams, Clare, Ahrens, Birgit, Alter, Peter, Anckers, Freja, van den Berge, Maarten, Blumchen, Katharina, Brusselle, Guy, Clarke, Graham W, Cunoosamy, Danen, Dahlén, Barbro, Dixey, Piers, Exley, Andrew, Frey, Urs, Gaillard, Erol A, Giovannini-Chami, Lisa, Grigg, Jonathan, Hartenstein, Diana, Heaney, Liam G, Karadag, Bülent, Kaul, Susanne, Kull, Inger, Licari, Amelia, Maitland-van der Zee, Anke H, Mahler, Vera, and Roberts, Graham
- Abstract
BACKGROUND: Effectiveness studies with biological therapies for asthma lack standardised outcome measures. The COMSA (Core Outcome Measures sets for paediatric and adult Severe Asthma) working group sought to develop Core Outcome Measures (COM) sets to facilitate better synthesis of data and appraisal of biologics in paediatric and adult asthma clinical studies.METHODS: COMSA utilised a multi-stakeholder consensus process among patients with severe asthma, adult, and paediatric clinicians, pharmaceutical representatives and health regulators from across Europe. Evidence included a systematic review of development, validity, and reliability of selected outcome measures plus a narrative review and a pan-European survey to better understand patients' and carers' views about outcome measures. It was discussed using a modified GRADE Evidence to Decision framework. Anonymous voting was conducted using predefined consensus criteria.RESULTS: Both adult and paediatric COM sets include forced expiratory volume in 1 s (FEV1) as z scores, annual frequency of severe exacerbations and maintenance oral corticosteroid use. Additionally, the paediatric COM set includes the Paediatric Asthma Quality of Life Questionnaire, and Asthma Control Test (ACT) or Childhood-ACT while the adult COM includes the Severe Asthma Questionnaire and the Asthma Control Questionnaire-6 (symptoms and rescue medication use reported separately).CONCLUSIONS: This patient-centred collaboration has produced two COM sets for paediatric and adult severe asthma. It is expected that they will inform the methodology of future clinical trials, enhance comparability of efficacy and effectiveness of biological therapies, and help assess their socioeconomic value. COMSA will inform definitions of non-response and response to biological therapy for severe asthma.
- Published
- 2022
34. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)
- Author
-
Khaleva, Ekaterina, primary, Rattu, Anna, additional, Brightling, Chris, additional, Bush, Andrew, additional, Bossios, Apostolos, additional, Bourdin, Arnaud, additional, Chung, Kian Fan, additional, Chaudhuri, Rekha, additional, Coleman, Courtney, additional, Dahlén, Sven-Erik, additional, Djukanovic, Ratko, additional, Deschildre, Antoine, additional, Fleming, Louise, additional, Fowler, Stephen J., additional, Gupta, Atul, additional, Hamelmann, Eckard, additional, Hashimoto, Simone, additional, Hedlin, Gunilla, additional, Koppelman, Gerard H., additional, Melén, Erik, additional, Murray, Clare S., additional, Pilette, Charles, additional, Porsbjerg, Celeste, additional, Pike, Katharine C., additional, Rusconi, Franca, additional, Williams, Clare, additional, Ahrens, Birgit, additional, Alter, Peter, additional, Anckers, Freja, additional, van den Berge, Maarten, additional, Blumchen, Katharina, additional, Brusselle, Guy, additional, Clarke, Graham W., additional, Cunoosamy, Danen, additional, Dahlén, Barbro, additional, Dixey, Piers, additional, Exley, Andrew, additional, Frey, Urs, additional, Gaillard, Erol A., additional, Giovannini-Chami, Lisa, additional, Grigg, Jonathan, additional, Hartenstein, Diana, additional, Heaney, Liam G., additional, Karadag, Bülent, additional, Kaul, Susanne, additional, Kull, Inger, additional, Licari, Amelia, additional, Maitland-van der Zee, Anke H., additional, Mahler, Vera, additional, Schoos, Ann-Marie M., additional, Nagakumar, Prasad, additional, Negus, Jenny, additional, Nielsen, Hanna, additional, Paton, James, additional, Pijnenburg, Mariëlle, additional, Ramiconi, Valeria, additional, Romagosa Vilarnau, Sofia, additional, Principe, Stefania, additional, Rutjes, Niels, additional, Saglani, Sejal, additional, Seddon, Paul, additional, Singer, Florian, additional, Staudinger, Heribert, additional, Turner, Steve, additional, Vijverberg, Susanne, additional, Winders, Tonya, additional, Yasinska, Valentyna, additional, and Roberts, Graham, additional
- Published
- 2022
- Full Text
- View/download PDF
35. Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
- Author
-
Frix, Anne-Noelle, primary, Heaney, Liam G., additional, Dahlén, Barbro, additional, Mihaltan, Florin, additional, Sergejeva, Svetlana, additional, Popović-Grle, Sanja, additional, Sedlak, Vratislav, additional, Lehtimäki, Lauri, additional, Bourdin, Arnaud, additional, Korn, Stephanie, additional, Zervas, Eleftherios, additional, Csoma, Zsuzsanna, additional, Lúðvíksdóttir, Dora, additional, Butler, Marcus, additional, Canonica, Giorgio Walter, additional, Grisle, Ineta, additional, Bieksiene, Kristina, additional, Ten Brinke, Anneke, additional, Kuna, Piotr, additional, Chaves Loureiro, Claudia, additional, Nenasheva, Natalia M., additional, Lazic, Zorica, additional, Škrgat, Sabina, additional, Ramos-Barbon, David, additional, Leuppi, Joerg, additional, Gemicioglu, Bilun, additional, Bossios, Apostolos, additional, Porsbjerg, Celeste M., additional, Bel, Elisabeth H., additional, Djukanovic, Ratko, additional, and Louis, Renaud, additional
- Published
- 2022
- Full Text
- View/download PDF
36. Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
- Author
-
Kamstrup, Peter, primary, Sand, Jannie Marie Bülow, additional, Ulrik, Charlotte Suppli, additional, Janner, Julie, additional, Rønn, Christian Philip, additional, Rønnow, Sarah Rank, additional, Leeming, Diana Julie, additional, Jensen, Sidse Graff, additional, Wilcke, Torgny, additional, Mathioudakis, Alexander G., additional, Miravitlles, Marc, additional, Lapperre, Therese, additional, Bendstrup, Elisabeth, additional, Frikke-Schmidt, Ruth, additional, Murray, Daniel D., additional, Itenov, Theis, additional, Bossios, Apostolos, additional, Nielsen, Susanne Dam, additional, Vestbo, Jørgen, additional, Biering-Sørensen, Tor, additional, Karsdal, Morten, additional, Jensen, Jens-Ulrik, additional, and Sivapalan, Pradeesh, additional
- Published
- 2022
- Full Text
- View/download PDF
37. Five-fold increase in use of inhaled corticosteroids over 18 years in the general adult population in West Sweden
- Author
-
Ekerljung, Linda, Bjerg, Anders, Bossios, Apostolos, Axelsson, Malin, Torén, Kjell, Wennergren, Göran, Lötvall, Jan, and Lundbäck, Bo
- Published
- 2014
- Full Text
- View/download PDF
38. MicroRNA-155 is essential for TH2-mediated allergen-induced eosinophilic inflammation in the lung
- Author
-
Malmhäll, Carina, Alawieh, Sahar, Lu, You, Sjöstrand, Margareta, Bossios, Apostolos, Eldh, Maria, and Rådinger, Madeleine
- Published
- 2014
- Full Text
- View/download PDF
39. COVID-19 vaccination in the setting of mastocytosis—Pfizer-BioNTech mRNA vaccine is safe and well tolerated
- Author
-
Lazarinis, Nikolaos, primary, Bossios, Apostolos, additional, and Gülen, Theo, additional
- Published
- 2022
- Full Text
- View/download PDF
40. Sex Disparities in Asthma Development and Clinical Outcomes: Implications for Treatment Strategies
- Author
-
Zhang, Guo Qiang, Ermis, Saliha Selin Özuygur, Rådinger, Madeleine, Bossios, Apostolos, Kankaanranta, Hannu, Nwaru, Bright, Tampere University, Clinical Medicine, and Seinäjoen keskussairaala VA
- Subjects
Journal of Asthma and Allergy ,3121 Internal medicine ,respiratory tract diseases - Abstract
Guo-Qiang Zhang,1 Saliha Selin Ãzuygur Ermis,1,2 Madeleine RÃ¥dinger,1 Apostolos Bossios,3,4 Hannu Kankaanranta,1,5,6 Bright Nwaru1,7 1Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 2Department of Respiratory Medicine, Dokuz Eylul University, İzmir, Turkey; 3Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden; 4Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden; 5Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; 6Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland; 7Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, SwedenCorrespondence: Bright Nwaru, Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, P.O. Box 424, Gothenburg, SE-405 30, Sweden, Tel +46 076 064 2614, Email bright.nwaru@gu.seAbstract: A gender-related disparity exists in asthma morbidity and mortality, which shifts at around puberty from a male predominance to a female predominance. This is clinically reflected in the fact that asthma that occurs in childhood (childhood-onset asthma) mainly affects boys, and that asthma that occurs in adulthood (adult-onset asthma) mainly affects women. Adult-onset asthma is often non-atopic, more severe, and associated with a poorer prognosis, thus posing a marked burden to womenâs health and healthcare system. Many factors have been indicated to explain this gender-related disparity, including sociocultural and environmental factors as well as biological sex differences (genetic, pulmonary and immunological factors). It has long been suggested that sex hormones may be implicated in at least these biological sex differences. Overall, the evidence remains equivocal for the role of most sex hormones in asthma pathogenesis and clinical outcomes. Well-designed randomized clinical trials are required assessing the potential preventive or therapeutic effects of hormonal contraceptives on asthma in women, thereby helping to advance the evidence to inform future practice guidelines. The mechanisms underlying the role of sex hormones in asthma are complex, and our understanding is not yet complete. Additional mechanistic studies elucidating sex hormone signaling pathways and their interactions involved in the pathogenesis and clinical manifestations of asthma will help to identify potential sex hormone-driven asthma endotypes and novel therapeutic targets, providing the basis for a more personalized asthma management strategy.Keywords: androgen, asthma, estrogen, progestogen, sex disparity, sex hormone
- Published
- 2022
41. Sex Disparities in Asthma Development and Clinical Outcomes: Implications for Treatment Strategies
- Author
-
Zhang,Guo-Qiang, Ãzuygur Ermis,Saliha Selin, RÃ¥dinger,Madeleine, Bossios,Apostolos, Kankaanranta,Hannu, Nwaru,Bright, Zhang,Guo-Qiang, Ãzuygur Ermis,Saliha Selin, RÃ¥dinger,Madeleine, Bossios,Apostolos, Kankaanranta,Hannu, and Nwaru,Bright
- Abstract
Guo-Qiang Zhang,1 Saliha Selin Ãzuygur Ermis,1,2 Madeleine RÃ¥dinger,1 Apostolos Bossios,3,4 Hannu Kankaanranta,1,5,6 Bright Nwaru1,7 1Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 2Department of Respiratory Medicine, Dokuz Eylul University, İzmir, Turkey; 3Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden; 4Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden; 5Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; 6Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland; 7Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, SwedenCorrespondence: Bright Nwaru, Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, P.O. Box 424, Gothenburg, SE-405 30, Sweden, Tel +46 076 064 2614, Email bright.nwaru@gu.seAbstract: A gender-related disparity exists in asthma morbidity and mortality, which shifts at around puberty from a male predominance to a female predominance. This is clinically reflected in the fact that asthma that occurs in childhood (childhood-onset asthma) mainly affects boys, and that asthma that occurs in adulthood (adult-onset asthma) mainly affects women. Adult-onset asthma is often non-atopic, more severe, and associated with a poorer prognosis, thus posing a marked burden to womenâs health and healthcare system. Many factors have been indicated to explain this gender-related disparity, including sociocultural and environmental factors as well as biological sex differences (genetic, pulmonary and immunological factors). It has long been suggested that sex hormones may be implicated in at least these biological sex differences. Overall, the evidence remains equivocal for the role of most sex hormones in asthma pathogenesis and clinical outcomes. Well-designed rando
- Published
- 2022
42. The effect of the COVID-19 pandemic on severe asthma care in Europe : will care change for good?
- Author
-
Eger, Katrien, Paroczai, Dora, Bacon, Alison, Schleich, Florence, Sergejeva, Svetlana, Bourdin, Arnaud, Vachier, Isabelle, Zervas, Eleftherios, Katsoulis, Konstantinos, Papapetrou, Dimosthenis, Kostikas, Konstantinos, Csoma, Zsuzsanna, Heffler, Enrico, Canonica, Giorgio Walter, Grisle, Ineta, Bieksiene, Kristina, Palacionyte, Jolita, Ten Brinke, Anneke, Hashimoto, Simone, Smeenk, Frank W. J. M., Braunstahl, Gert-Jan, van der Sar, Simone, Mihaltan, Florin, Nenasheva, Natalia, Peredelskaya, Marina, Zvezdin, Biljana, Cekerevac, Ivan, Hromis, Sanja, Cupurdija, Vojislav, Lazic, Zorica, Milenkovic, Branislava, Dimic-Janjic, Sanja, Yasinska, Valentyna, Dahlen, Barbro, Bossios, Apostolos, Lazarinis, Nikolaos, Aronsson, David, Egesten, Arne, Munir, Abul Kashem Mohammad, Ahlbeck, Lars, Janson, Christer, Skrgat, Sabina, Edelbaher, Natalija, Leuppi, Joerg, Jaun, Fabienne, Rudiger, Jochen, Pavlov, Nikolay, Gianella, Pietro, Fischer, Reta, Charbonnier, Florian, Chaudhuri, Rekha, Smith, Steven James, Doe, Simon, Fawdon, Michelle, Masoli, Matthew, Heaney, Liam, Haitchi, Hans Michael, Kurukulaaratchy, Ramesh, Fulton, Olivia, Frankemolle, Betty, Gibson, Toni, Needham, Karen, Howarth, Peter, Djukanovic, Ratko, Bel, Elisabeth, Hyland, Michael, Eger, Katrien, Paroczai, Dora, Bacon, Alison, Schleich, Florence, Sergejeva, Svetlana, Bourdin, Arnaud, Vachier, Isabelle, Zervas, Eleftherios, Katsoulis, Konstantinos, Papapetrou, Dimosthenis, Kostikas, Konstantinos, Csoma, Zsuzsanna, Heffler, Enrico, Canonica, Giorgio Walter, Grisle, Ineta, Bieksiene, Kristina, Palacionyte, Jolita, Ten Brinke, Anneke, Hashimoto, Simone, Smeenk, Frank W. J. M., Braunstahl, Gert-Jan, van der Sar, Simone, Mihaltan, Florin, Nenasheva, Natalia, Peredelskaya, Marina, Zvezdin, Biljana, Cekerevac, Ivan, Hromis, Sanja, Cupurdija, Vojislav, Lazic, Zorica, Milenkovic, Branislava, Dimic-Janjic, Sanja, Yasinska, Valentyna, Dahlen, Barbro, Bossios, Apostolos, Lazarinis, Nikolaos, Aronsson, David, Egesten, Arne, Munir, Abul Kashem Mohammad, Ahlbeck, Lars, Janson, Christer, Skrgat, Sabina, Edelbaher, Natalija, Leuppi, Joerg, Jaun, Fabienne, Rudiger, Jochen, Pavlov, Nikolay, Gianella, Pietro, Fischer, Reta, Charbonnier, Florian, Chaudhuri, Rekha, Smith, Steven James, Doe, Simon, Fawdon, Michelle, Masoli, Matthew, Heaney, Liam, Haitchi, Hans Michael, Kurukulaaratchy, Ramesh, Fulton, Olivia, Frankemolle, Betty, Gibson, Toni, Needham, Karen, Howarth, Peter, Djukanovic, Ratko, Bel, Elisabeth, and Hyland, Michael
- Abstract
Background The coronavirus disease 2019 (COVID-19) pandemic has put pressure on healthcare services, forcing the reorganisation of traditional care pathways. We investigated how physicians taking care of severe asthma patients in Europe reorganised care, and how these changes affected patient satisfaction, asthma control and future care. Methods In this European-wide cross-sectional study, patient surveys were sent to patients with a physician-diagnosis of severe asthma, and physician surveys to severe asthma specialists between November 2020 and May 2021. Results 1101 patients and 268 physicians from 16 European countries contributed to the study. Common physician-reported changes in severe asthma care included use of video/phone consultations (46%), reduced availability of physicians (43%) and change to home-administered biologics (38%). Change to phone/video consultations was reported in 45% of patients, of whom 79% were satisfied or very satisfied with this change. Of 709 patients on biologics, 24% experienced changes in biologic care, of whom 92% were changed to home-administered biologics and of these 62% were satisfied or very satisfied with this change. Only 2% reported worsening asthma symptoms associated with changes in biologic care. Many physicians expect continued implementation of video/phone consultations (41%) and home administration of biologics (52%). Conclusions Change to video/phone consultations and home administration of biologics was common in severe asthma care during the COVID-19 pandemic and was associated with high satisfaction levels in most but not all cases. Many physicians expect these changes to continue in future severe asthma care, though satisfaction levels may change after the pandemic.
- Published
- 2022
- Full Text
- View/download PDF
43. Heterogeneity in the use of biologics for severe asthma in Europe:a SHARP ERS study
- Author
-
Frix, Anne Noelle, Heaney, Liam G., Dahlén, Barbro, Mihaltan, Florin, Sergejeva, Svetlana, Popović-Grle, Sanja, Sedlak, Vratislav, Lehtimäki, Lauri, Bourdin, Arnaud, Korn, Stephanie, Zervas, Eleftherios, Csoma, Zsuzsanna, Lúðvíksdóttir, Dora, Butler, Marcus, Canonica, Giorgio Walter, Grisle, Ineta, Bieksiene, Kristina, Ten Brinke, Anneke, Kuna, Piotr, Loureiro, Claudia Chaves, Nenasheva, Natalia M., Lazic, Zorica, Škrgat, Sabina, Ramos-Barbon, David, Leuppi, Joerg, Gemicioglu, Bilun, Bossios, Apostolos, Porsbjerg, Celeste M., Bel, Elisabeth H., Djukanovic, Ratko, Louis, Renaud, Frix, Anne Noelle, Heaney, Liam G., Dahlén, Barbro, Mihaltan, Florin, Sergejeva, Svetlana, Popović-Grle, Sanja, Sedlak, Vratislav, Lehtimäki, Lauri, Bourdin, Arnaud, Korn, Stephanie, Zervas, Eleftherios, Csoma, Zsuzsanna, Lúðvíksdóttir, Dora, Butler, Marcus, Canonica, Giorgio Walter, Grisle, Ineta, Bieksiene, Kristina, Ten Brinke, Anneke, Kuna, Piotr, Loureiro, Claudia Chaves, Nenasheva, Natalia M., Lazic, Zorica, Škrgat, Sabina, Ramos-Barbon, David, Leuppi, Joerg, Gemicioglu, Bilun, Bossios, Apostolos, Porsbjerg, Celeste M., Bel, Elisabeth H., Djukanovic, Ratko, and Louis, Renaud
- Abstract
Introduction Treatment with biologics for severe asthma is informed by international and national guidelines and defined by national regulating bodies, but how these drugs are used in real-life is unknown. Materials and methods The European Respiratory Society (ERS) SHARP Clinical Research Collaboration conducted a three-step survey collecting information on asthma biologics use in Europe. Five geographically distant countries defined the survey questions, focusing on seven end-points: biologics availability and financial issues, prescription and administration modalities, inclusion criteria, continuation criteria, switching biologics, combining biologics and evaluation of corticosteroid toxicity. The survey was then sent to SHARP National Leads of 28 European countries. Finally, selected questions were submitted to a broad group of 263 asthma experts identified by national societies. Results Availability of biologics varied between countries, with 17 out of 28 countries having all five existing biologics. Authorised prescribers (pulmonologists and other specialists) also differed. In-hospital administration was the preferred deliverance modality. While exacerbation rate was used as an inclusion criterion in all countries, forced expiratory volume in 1 s was used in 46%. Blood eosinophils were an inclusion criterion in all countries for interleukin-5 (IL-5)-targeted and IL-4/IL-13-targeted biologics, with varying thresholds. There were no formally established criteria for continuing biologics. Reduction in exacerbations represented the most important benchmark, followed by improvement in asthma control and quality of life. Only 73% (191 out of 263) of surveyed clinicians assessed their patients for corticosteroid-induced toxicity. Conclusion Our study reveals important heterogeneity in the use of asthma biologics across Europe. To what extent this impacts on clinical outcomes relevant to patients and healthcare services needs further investigation.
- Published
- 2022
44. Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD:A Cohort Sub-Study in a Randomized Trial Population
- Author
-
Kamstrup, Peter, Sand, Jannie Marie Bulow, Ulrik, Charlotte Suppli, Janner, Julie, Ronn, Christian Philip, Ronnow, Sarah Rank, Leeming, Diana Julie, Jensen, Sidse Graff, Wilcke, Torgny, Mathioudakis, Alexander G., Miravitlles, Marc, Lapperre, Therese, Bendstrup, Elisabeth, Frikke-Schmidt, Ruth, Murray, Daniel D., Itenov, Theis, Bossios, Apostolos, Nielsen, Susanne Dam, Vestbo, Jorgen, Biering-Sorensen, Tor, Karsdal, Morten, Jensen, Jens-Ulrik, Sivapalan, Pradeesh, Kamstrup, Peter, Sand, Jannie Marie Bulow, Ulrik, Charlotte Suppli, Janner, Julie, Ronn, Christian Philip, Ronnow, Sarah Rank, Leeming, Diana Julie, Jensen, Sidse Graff, Wilcke, Torgny, Mathioudakis, Alexander G., Miravitlles, Marc, Lapperre, Therese, Bendstrup, Elisabeth, Frikke-Schmidt, Ruth, Murray, Daniel D., Itenov, Theis, Bossios, Apostolos, Nielsen, Susanne Dam, Vestbo, Jorgen, Biering-Sorensen, Tor, Karsdal, Morten, Jensen, Jens-Ulrik, and Sivapalan, Pradeesh
- Abstract
Cardiovascular diseases are common in patients with chronic obstructive pulmonary disease (COPD). Clot formation and resolution secondary to systemic inflammation may be a part of the explanation. The aim was to determine whether biomarkers of clot formation (products of von Willebrand Factor formation and activation) and clot resolution (product of fibrin degeneration) during COPD exacerbation predicted major cardiovascular events (MACE). The cohort was based on clinical data and biobank plasma samples from a trial including patients admitted with an acute exacerbation of COPD (CORTICO-COP). Neo-epitope biomarkers of formation and the activation of von Willebrand factor (VWF-N and V-WFA, respectively) and cross-linked fibrin degradation (X-FIB) were assessed using ELISAs in EDTA plasma at the time of acute admission, and analyzed for time-to-first MACE within 36 months, using multivariable Cox proportional hazards models. In total, 299/318 participants had samples available for analysis. The risk of MACE for patients in the upper quartile of each biomarker versus the lower quartile was: X-FIB: HR 0.98 (95% CI 0.65-1.48), VWF-N: HR 1.56 (95% CI 1.07-2.27), and VWF-A: HR 0.78 (95% CI 0.52-1.16). Thus, in COPD patients with an acute exacerbation, VWF-N was associated with future MACE and warrants further studies in a larger population.
- Published
- 2022
45. The effect of the COVID-19 pandemic on severe asthma care in Europe: will care change for good?
- Author
-
Eger, Katrien, primary, Paroczai, Dora, additional, Bacon, Alison, additional, Schleich, Florence, additional, Sergejeva, Svetlana, additional, Bourdin, Arnaud, additional, Vachier, Isabelle, additional, Zervas, Eleftherios, additional, Katsoulis, Konstantinos, additional, Papapetrou, Dimosthenis, additional, Kostikas, Konstantinos, additional, Csoma, Zsuzsanna, additional, Heffler, Enrico, additional, Canonica, Giorgio Walter, additional, Grisle, Ineta, additional, Bieksiene, Kristina, additional, Palacionyte, Jolita, additional, ten Brinke, Anneke, additional, Hashimoto, Simone, additional, Smeenk, Frank W.J.M., additional, Braunstahl, Gert-Jan, additional, van der Sar, Simone, additional, Mihălţan, Florin, additional, Nenasheva, Natalia, additional, Peredelskaya, Marina, additional, Zvezdin, Biljana, additional, Čekerevac, Ivan, additional, Hromiš, Sanja, additional, Ćupurdija, Vojislav, additional, Lazic, Zorica, additional, Milenkovic, Branislava, additional, Dimic-Janjic, Sanja, additional, Yasinska, Valentyna, additional, Dahlén, Barbro, additional, Bossios, Apostolos, additional, Lazarinis, Nikolaos, additional, Aronsson, David, additional, Egesten, Arne, additional, Munir, Abul Kashem Mohammad, additional, Ahlbeck, Lars, additional, Janson, Christer, additional, Škrgat, Sabina, additional, Edelbaher, Natalija, additional, Leuppi, Joerg, additional, Jaun, Fabienne, additional, Rüdiger, Jochen, additional, Pavlov, Nikolay, additional, Gianella, Pietro, additional, Fischer, Reta, additional, Charbonnier, Florian, additional, Chaudhuri, Rekha, additional, Smith, Steven James, additional, Doe, Simon, additional, Fawdon, Michelle, additional, Masoli, Matthew, additional, Heaney, Liam, additional, Haitchi, Hans Michael, additional, Kurukulaaratchy, Ramesh, additional, Fulton, Olivia, additional, Frankemölle, Betty, additional, Gibson, Toni, additional, Needham, Karen, additional, Howarth, Peter, additional, Djukanovic, Ratko, additional, Bel, Elisabeth, additional, and Hyland, Michael, additional
- Published
- 2022
- Full Text
- View/download PDF
46. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c
- Author
-
Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szépfalusi, Zsolt, Pohl, Wolfgang, Hötzenecker, Wolfram, Rosenkranz, Alexander, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Claus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Mülleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink Wagner, Antje, Horak, Fritz, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Mübecell, Matricardi, Paolo M., Spertini, François, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Larent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Jürgen, O´Mahony, Liam, Knol, Edward, del Giacco, Stefano, Chivato, Tomás, Bousquet, Jean, Zuberbier, Torsten, Akdis, Cezmi, and Jutel, Marek
- Subjects
Titel ,SARS-CoV-2 ,Medizin ,Immunology and Allergy ,Omalizumab ,Benralizumab ,Dupilumab ,Reslizumab ,Covid-19 ,Telemedizin ,Mepolizumab - Published
- 2020
47. ROSE: radiology, obstruction, symptoms and exposure – a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group
- Author
-
Traversi, Letizia, primary, Miravitlles, Marc, additional, Martinez-Garcia, Miguel Angel, additional, Shteinberg, Michal, additional, Bossios, Apostolos, additional, Dimakou, Katerina, additional, Jacob, Joseph, additional, Hurst, John R., additional, Paggiaro, Pier Luigi, additional, Ferri, Sebastian, additional, Hillas, Georgios, additional, Vogel-Claussen, Jens, additional, Dettmer, Sabine, additional, Aliberti, Stefano, additional, Chalmers, James D., additional, and Polverino, Eva, additional
- Published
- 2021
- Full Text
- View/download PDF
48. Translation and validation of the Quality-of-Life Bronchiectasis questionnaire in Swedish, and correlation with clinical outcomes
- Author
-
Ghosh, Pia, primary, Gerhardson, Ingrid, additional, Middelveld, Roelinde, additional, Ek, Alexandra, additional, Panagiotou, Amalia, additional, Dahlén, Sven-Erik, additional, Dahlén, Barbro, additional, and Bossios, Apostolos, additional
- Published
- 2021
- Full Text
- View/download PDF
49. Adult women with asthma and diabetes have increased body weight and fat percentage compared to women with only diabetes
- Author
-
Bossios, Apostolos, primary, Andersson, Daniel P., additional, Eriksson-Hogling, Daniel, additional, and Rydén, Mikael, additional
- Published
- 2021
- Full Text
- View/download PDF
50. Sensitization to aeroallergens is dominant in overweight to obese asthmatic males but not in females
- Author
-
Nwaru, Bright, primary, Kankaanranta, Hannu, additional, Rådinger, Madeleine, additional, Lötvall, Jan, additional, Lundbäck, Bo, additional, Ekerljung, Linda, additional, and Bossios, Apostolos, additional
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.